4scar-gd2
B Cell Lymphoma (BCL)
Shenzhen Geno-Immune Medical InstitutePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
316 Active assets in the B Cell Lymphoma (BCL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINDESINE Children's Cancer Group, China | Phase 4 | BBB |
Odronextamab University of Birmingham | Phase 3 | BBB |
cc-5013 Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Cytosin-Arabinosid Children's Cancer Group, China | Phase 4 | BBB |
METHOTREXATE Children's Cancer Group, China | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
4scar-gd2 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →